Results 31 to 40 of about 1,273,410 (345)

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

New England Journal of Medicine, 2004
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone ...
D. Petrylak, C. Tangen, M. Hussain, P. Lara, Jeffrey A. Jones, M. Taplin, P. Burch, D. Berry, C. Moinpour, M. Kohli, M. Benson, E. Small, D. Raghavan, E. Crawford   +13 more
semanticscholar   +1 more source

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

New England Journal of Medicine, 2015
BACKGROUND Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT ...
C. Sweeney, Yu‐Hui Chen, M. Carducci, Glenn Liu, D. Jarrard, M. Eisenberger, Y. Wong, N. Hahn, M. Kohli, M. Cooney, R. Dreicer, N. Vogelzang, J. Picus, D. Shevrin, M. Hussain, Jorge A. Garcia, R. DiPaola   +16 more
semanticscholar   +1 more source

Prostatitis

Annual Review of Medicine, 1975
Several distinct types of prostatitis, or prostatitis syndromes, are now recognized. The most common forms include acute and chronic bacterial prostatitis, nonbacterial prostatitis, and prostatodynia. Bacterial prostatitis, caused mainly by coliform bacteria, Pseudomonas, and Enterococcus faecalis, is often difficult to cure and usually requires ...
openaire   +5 more sources

Divergent clonal evolution of castration resistant neuroendocrine prostate cancer

Nature Network Boston, 2016
An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to absent AR expression and often have neuroendocrine features.
H. Beltran, D. Prandi, J. Mosquera, M. Benelli, L. Puca, J. Cyrta, C. Marotz, Eugenia G. Giannopoulou, B. V. Chakravarthi, S. Varambally, S. Tomlins, D. Nanus, S. Tagawa, E. V. Van Allen, O. Elemento, A. Sboner, L. Garraway, M. Rubin, F. Demichelis   +18 more
semanticscholar   +1 more source

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

New England Journal of Medicine, 2014
BACKGROUND The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor.
E. Antonarakis, Changxue Lu, Hao Wang, Brandon S. Luber, M. Nakazawa, J. Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L. Fedor, T. Lotan, Qizhi Zheng, A. D. De Marzo, J. Isaacs, W. Isaacs, R. Nadal, C. Paller, S. Denmeade, M. Carducci, M. Eisenberger, Jun Luo   +20 more
semanticscholar   +1 more source

A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness

Scientific Reports, 2017
Short tandem repeats (STRs) are repetitive sequences of a polymorphic stretch of two to six nucleotides. We hypothesized that STRs are associated with prostate cancer development and/or progression. We undertook RNA sequencing analysis of prostate tumors
John Lai, Leire Moya, Jiyuan An, Andrea Hoffman, Srilakshmi Srinivasan, Janaththani Panchadsaram, Carina Walpole, Joanna L. Perry-Keene, Suzanne Chambers, Australian Prostate Cancer BioResource, Melanie L. Lehman, Colleen C. Nelson, Judith A. Clements, Jyotsna Batra   +13 more
doaj   +1 more source

Autophagy in cancer and protein conformational disorders

FEBS Letters, EarlyView.
Autophagy plays a crucial role in numerous biological processes, including protein and organelle quality control, development, immunity, and metabolism. Hence, dysregulation or mutations in autophagy‐related genes have been implicated in a wide range of human diseases.
Sergio Attanasio
wiley   +1 more source

Evaluating whether Prostate Cancer UK’s risk checker is a help or hindrance to prostate-specific antigen testing policy: a mixed-methods study

BJGP Open
Background: The UK has an informed choice testing policy for prostate cancer. The prostate-specific antigen (PSA) blood test is available for free to any man aged ≥50 years who requests it and has been informed of the harms and benefits.
Natalia Norori, Chiara de Biase, Yui Hang Wong, Sadie Robson Crabtree, Matt Cox, Esther Appleby, Andrew Seggie, Rachel Brown, Amy Rylance   +8 more
doaj   +1 more source

Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis

BJUI Compass, 2023
Background Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. We performed a systematic review and meta‐analysis to evaluate the prevalence of genomic alterations in NEPC and better understand its molecular features to ...
Junru Chen, Mingchen Shi, Stephen Yiu Chuen Choi, Yu Wang, Dong Lin, Hao Zeng, Yuzhuo Wang   +6 more
doaj   +1 more source

Enzalutamide in metastatic prostate cancer before chemotherapy.

New England Journal of Medicine, 2014
BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy.
T. Beer, A. Armstrong, D. Rathkopf, Y. Loriot, Cora N. Sternberg, C. Higano, P. Iversen, S. Bhattacharya, J. Carles, S. Chowdhury, Ian D. Davis, J. D. de Bono, Christopher P Evans, K. Fizazi, Anthony M. Joshua, Choung-Soo Kim, G. Kimura, P. Mainwaring, H. Mansbach, K. Miller, S. Noonberg, F. Perabo, D. Phung, F. Saad, H. Scher, M. Taplin, P. Venner, B. Tombal   +27 more
semanticscholar   +1 more source